2015
DOI: 10.1089/mdr.2014.0162
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic Effects Between Thioxanthones and Oxacillin Against Methicillin-ResistantStaphylococcus aureus

Abstract: The extensive use of antimicrobials is leaving medicine with few effective therapeutic options to treat many infections due to the fact that many organisms developed resistance to commonly used drugs. It is therefore pertinent to search not only for new antimicrobials but also for compounds able to restore or potentiate the activity of existing antibiotics. We have screened a library consisting of 40 (thio)xanthone derivatives for antibacterial activity and possible synergistic effects when used in combination… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
28
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 51 publications
0
28
1
Order By: Relevance
“…In addition, given the importance of the S. aureus pathogenicity and its ability to acquire resistance, new ways to combat this pathogen must be developed, among them is combination therapy using compounds that act or not on the same target. Therefore, to test the combining action became a key step in phytochemical studies (Wagner and Ulrich-Merzenich, 2009 ; Bessa et al, 2015 ; dos Santos et al, 2015 ). CL and CR extracts were able to increase the effectiveness of this antibiotic, mainly through synergistic interaction.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, given the importance of the S. aureus pathogenicity and its ability to acquire resistance, new ways to combat this pathogen must be developed, among them is combination therapy using compounds that act or not on the same target. Therefore, to test the combining action became a key step in phytochemical studies (Wagner and Ulrich-Merzenich, 2009 ; Bessa et al, 2015 ; dos Santos et al, 2015 ). CL and CR extracts were able to increase the effectiveness of this antibiotic, mainly through synergistic interaction.…”
Section: Discussionmentioning
confidence: 99%
“…CL and CR extracts were able to increase the effectiveness of this antibiotic, mainly through synergistic interaction. Some plant-derived products have demonstrated the ability to reverse resistance to oxacillin (Jenkins and Cooper, 2012 ; Bessa et al, 2015 ), and the perspective is that the use of therapies based on the combination of phytochemicals and antibiotics grow in conventional medicine, as it may reduce the likelihood of dose-dependent toxicity and mutagenicity of antimicrobials (Boucher and Tam, 2006 ; Wagner and Ulrich-Merzenich, 2009 ).…”
Section: Discussionmentioning
confidence: 99%
“…An initial screening of the antibacterial activity of the compounds was performed by the disk diffusion method as previously described [ 27 , 28 ]. Briefly, sterile 6 mm blank paper disks (Oxoid, Basingstoke, UK) impregnated with 15 µg of each compound were placed on MH agar plates inoculated with the bacteria.…”
Section: Methodsmentioning
confidence: 99%
“…In order to evaluate the combined effect of the compounds and clinically relevant antimicrobial drugs, a screening was conducted using the disk diffusion method, as previously described [ 27 , 28 ]. A set of antibiotic disks (Oxoid, Basingstoke, UK), to which the isolates were resistant, was selected: cefotaxime (CTX, 30 µg) for E. coli SA/2, oxacillin (OX, 1 µg) for S. aureus 66/1, and vancomycin (VA, 30 µg) for E. faecalis B3/101.…”
Section: Methodsmentioning
confidence: 99%
“…In order to evaluate the combined effect of the compounds and clinically relevant antimicrobial drugs, a screening was conducted using the disk diffusion method, as previously described [ 38 , 39 ]. A set of antibiotic disks (Oxoid, Basingstoke, UK) to which the isolates were resistant was selected: cefotaxime (CTX, 30 µg) for E. coli SA/2, oxacillin (OX, 1 µg) for S. aureus 66/1, and vancomycin (VA, 30 µg) for E. faecalis B3/101.…”
Section: Methodsmentioning
confidence: 99%